<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In nine patients with <z:hpo ids='HP_0005575'>hemolytic-uremic syndrome</z:hpo>, the plasma activity and plasma concentrations of antithrombin III were determined on admission to the hospital and during the clinical course of the disease </plain></SENT>
<SENT sid="1" pm="."><plain>Hemodialysis was necessary in six of the patients </plain></SENT>
<SENT sid="2" pm="."><plain>In seven children the plasma AT III activity was moderately to markedly below the lower limit of <z:mpath ids='MPATH_458'>normal</z:mpath> at 75%, and did not rise after plasmapheresis with fresh frozen plasma </plain></SENT>
<SENT sid="3" pm="."><plain>Replacement therapy with AT III concentrate was started in these patients </plain></SENT>
<SENT sid="4" pm="."><plain>During the first 2 days an average dose of AT III concentrate of 2.1 U/kg in 24 h was necessary to raise plasma AT III activity by 1% </plain></SENT>
<SENT sid="5" pm="."><plain>No side effects were observed </plain></SENT>
<SENT sid="6" pm="."><plain>An already pre-existing procoagulant status and the administration of <z:chebi fb="5" ids="28304">heparin</z:chebi> may lead to AT III deficiency in <z:hpo ids='HP_0005575'>hemolytic-uremic syndrome</z:hpo> </plain></SENT>
</text></document>